Hepatocellular cancer care: Cost is important but only one factor of disease burden

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 10-12

  Kanwal, Fasiha ^a   El Serag, Hashem B ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER SCREENING; EDITORIAL; HEALTH CARE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; LIVER CELL CARCINOMA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LIVER NEOPLASMS; MEDICARE; PAIN; QUALITY OF LIFE; SEER PROGRAM; UNITED STATES;

EID: 56949095414     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.10.012     Document Type: Editorial

References (11)

1. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
2. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., and El-Serag H.B. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 (2004) 1372-1380
3. Greenlee R., Hill-Harmon M., Murray T., and Thun M. Cancer statistics, 2001. Cancer J Clin 51 (2001) 15-36
4. Steel J.L., Chopra K., Olek M.C., and Carr B.I. Health-related quality of life: hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res 16 (2007) 203-215
5. Lang K., Danchenko N., Gondek K., Shah S., and Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 50 (2009) 89-99
6. SEER-Medicare linked database. Available from: http://healthservices.cancer.gov/seermedicare/. Accessed October 20, 2008.
7. El-Serag H.B., Marrero J.A., Rudolph L., and Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134 (2008) 1752-1763
8. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
9. Ioannou G.N., Perkins J.D., and Carithers Jr. R.L. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 134 (2008) 1342-1351
10. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
11. McMahon B.J., Alberts S.R., Wainwright R.B., Bulkow L., and Lanier A.P. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 150 (1990) 1051-1054